Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2018

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

pharmaceutical companies pharma intelligence

The partner of choice for pharmaceutical companies

Bring game-changing drugs to market more efficiently. We’ll help you understand the competition to hone in on your strategies to improve healthcare and patient outcomes.

Get drugs to market faster

adevelopment partner pharma intelligence

The right drugs developed at the right time transform pharmaceutical and biotechnology companies and improve patients’ lives. But the process is long and complex, taking place in an ever-changing, intensely competitive arena.

How we help
As the trusted pharma research partner of the top 50 global pharmaceutical companies, we provide reliable, timely intelligence and insights to help you every step of the way during drug development.

We can help you:

Optimize your clinical trials
Stay ahead of the competition by fully understanding future patient needs
Tailor your portfolio and commercial strategies to market needs
Identify opportunities and overcome potential threats across your pipeline
Stay current and be prepared for market shifts
Access historical success rates, and development and regulatory durations from a large number of perspectives

Our unique strengths

Identify market opportunities

Understand where future drug and development opportunities lie with access to the industry’s leading forecasts and behind-the-headlines analysis.

Capitalize on treatment trends

Keep on top of global trends and access source information on the impact of developing technologies.

Approach reimbursement proactively

Our reimbursement analysis can assist your business planning – both at the early stages of product development and long after product launch.

View competitor activity

Get unique competitor insight with our detailed reviews of your competitors’ clinical trials and our ability to track all drugs in development.

View more
View Less

Relevant products

Thought leadership

Key benefits:

Build brand credibility
Generate Leads
Effective reporting

Awareness

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Effective reporting

Lead generation

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Measurable results

View all content

Scrip

Tech Transfer Roundup: How To Protect Downstream Rights

By Joseph Haas 12 Sep 2018

A review of tech transfer deals over 10 years shows that licensees often protect their value positions to limit royalties paid out to licensors. Meanwhile, licensors often protect their future rights with language recognizing that additional parties may be involved in producing a final product.

Topic Digital Health

View article
Scrip

Multiple Myeloma: A Growth Market Set To Shrink As Revlimid Generics Hit

By Mandy Jackson 12 Sep 2018

Despite several new entrants to the multiple myeloma market, Datamonitor Healthcare forecasts that drug sales between 2017 and 2026 will peak in 2022 when Revlimid generics hit the market. J&J's Darzalex will become the new best-seller, but generate a fraction of Revlimid's sales.

Topic Cancer Drug development landscape

View article
Scrip

INFOGRAPHIC: Patent Losses Characterize Japan's Challenging Pharma Future

By Jo Shorthouse 06 Sep 2018

Although 10 of Japan’s largest pharma companies look set to add $11bn in revenues over the next nine years, a CAGR of only 1% reflects an expected $4.8bn in patent expiries, leaving Japanese pharma heads relying on innovation for the next phase of the region’s major wins.

Topic Business strategies

View article
Scrip

Art Of War: Why Pharma Must Do Digital Dance In China

By Brian Yang 06 Sep 2018

“Winning the war without fighting. Using five types of fire attacks.” Sounds familiar? Sun Tzu's 2,000 year-old wisdom on the art of war is echoing down the ages, and winning in China today means that pharma needs to embrace a digital strategy more than ever before.

Topic Digital Health

View article
Scrip

Chindia Generics: A Dream or Reality?

By Brian Yang 30 Aug 2018

Meeting and greeting is necessary, as is the right form of partnership and getting everyone on board. But as Indian drug makers learn the ropes of entering the complex Chinese market, the seemingly natural fit may still have a long way to go.

Topic Business strategies

View article
Scrip

Shire Could Reclaim HAE Prophylaxis Market From CSL Behring

By Joseph Haas 30 Aug 2018

Offering better efficacy than Shire’s existing HAE therapies and dosing convenience compared to CSL Behring’s prophylactic Haegarda, the specialty pharma may take back market share lost to its competitor and consolidate its leadership in the space.

Topic FDA

View article
Scrip

A timeline of the Takeda/Shire merger

By Mike Ward 28 Aug 2018

A staple of consumer magazines and tabloid newspapers involves coverage of celebrity relationships – who has been seen together? Who is dating? Will they become a permanent item? And are they going to live happily ever after? Readers can’t seem to get enough of it. Interestingly, while maybe not so racy as the celebrity goings-on, pharma industry watchers are keen to follow company couplings. Talk of mergers and acquisitions, one of the ways that companies can build scale, always attracts attention.

Topic Business strategies Company analysis

View interactive data
Rose Sheet

Toxicity Testing For Topical Drugs, Sunscreens Included, On Tap In US FDA Workshop

By Ryan Nelson 23 Aug 2018

While FDA does not identify specific product types on the agenda for its public workshop on approaches in skin toxicity testing for topical drug products, advocacy and trade groups anticipate sunscreen ingredient testing could be among the discussion topics. Product expansions have been stifled by regulatory concerns, drawing particular attention from the public health community.

Topic FDA

View article
Scrip

Under The Radar Potential Small Cap Takeover Targets

By Joseph Haas 23 Aug 2018

Looking back at the second quarter, PharmaVitae analysts have selected 10 biopharma companies with market caps under $3bn they think are primed for acquisition – and the likely candidates for a buy-out.

Topic Business strategies BioPharmaceutical Deal trends

View article
Scrip

Japan Approval Another Boost For Tagrisso in 1L NSCLC

By Ian Haydock 23 Aug 2018

Following a priority review, Japan has approved AstraZeneca’s Tagrisso for the first-line treatment of inoperable or recurrent EGFR mutation-positive NSCLC, further strengthening the drug’s position in this setting.

Topic Cancer

View article
Awareness

Global Generics Podcast 2018

22 Aug 2018

Listen to this podcast with Generics bulletin editor Aidan Fry and deputy editor David Wallace. The Global Generics & Biosimilars Awards reward ‘best practice’ in the two industries, while at the same time encouraging improvements in every aspect of the way business is conducted.

Full podcast
Trialtrove

2017 Completed Trials

By Christine Blazynski, PhD 22 Aug 2018

As Informa Pharma Intelligence has done for the past three years, this analysis examines the landscape of industry-sponsored clinical trials completed during 2017, of which there were a total of 3,534 Phase I through Phase III/IV. The nearly 700 trials terminated in 2017 were not included in this analysis.

Topic Clinical trials

View white paper
Scrip

Novo's Oral Semaglutide Passes PIONEER 2, But Weight Loss Result A Bit Disappointing

By Emily Hayes 22 Aug 2018

In second Phase III diabetes study to report, oral GLP-1 agonist semaglutide misses some weight loss goals when compared with Boehringer/Lilly's SGLT-2 inhibitor Jardiance.

Topic Drug approval Drug development landscape Drug review

View article
Scrip

Missing In Action: China’s Best Shot In Ebola Vaccine Race

By Brian Yang 22 Aug 2018

As the Congo grapples with the latest outbreak of Ebola, China has approved its first domestically developed vaccine in record time, hailing it a national innovation champion. But as the World Health Organization starts vaccinations in Africa, can China make the cut and compete with global players including Merck & Co?

Topic Vaccines

View article
Scrip

How Ovarian Cancer Maintenance Therapies Stack Up On Costs And Value

By Emily Hayes 22 Aug 2018

With new branded immunotherapy-based double- or triple-drug combinations on the way, there is greater scrutiny of costs and efficiency.

Topic Cancer

View article

Latest headlines

Scrip

19 Sep 2018

Spectrum To Test Poziotinib's Potential As First Line Treatment Of Exon 20 Mutant NSCLC

Link
Scrip

19 Sep 2018

ICON CEO: CROs Must Be Aware Of Threat Posed By Big Tech

Link
Scrip

19 Sep 2018

Executives On The Move: New CEOs Vaxil Bio and Akero Therapeutics, with Some Big Pharma Execs Joining Smaller Companies

Link
Scrip

18 Sep 2018

Tildrakizumab Set For Europe Debut - Can It Make A Dent?

Link
Scrip

18 Sep 2018

Novo Nordisk Cuts 400 Jobs In R&D Reshuffle As It Broadens Its Horizons

Link
Scrip

18 Sep 2018

Viking’s Liver Fat Reduction Data Portend A New Competitor In NASH

Link
Scrip

18 Sep 2018

Pfizer Eyes First-To-Market Opportunity In Alopecia

Link
Scrip

18 Sep 2018

Boehringer Ingelheim Is Getting Bets In Early In IO Space

Link
Scrip

18 Sep 2018

Assessing Artios: $83m Series B, Big-Name Investors, Nothing In The Clinic

Link
Scrip

18 Sep 2018

Asia Deal Watch: BIOCAD, Shanghai Pharma Agree On Pair Of Russian/Chinese Joint Ventures

Link
Scrip

18 Sep 2018

Xelpros Approval Adds Spark To Sun’s Site Too?

Link
Scrip

17 Sep 2018

Almirall Taps Evotec For Novel Dermatology Mechanism

Link
Scrip

17 Sep 2018

Interview: Korea's Enzychem Eyes Global Expansion Via Nature-Inspired Drug

Link
Scrip

17 Sep 2018

Novo Nordisk CEO Hopes Tresiba Can Re-Enter Germany On A Higher Price

Link
Scrip

17 Sep 2018

Realm Reaches End of The Road And Seeks Buyer

Link

Next steps

Request a live demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 908 547 2200
UK & Europe : +44 (20) 337 73737
Australia : +61 2 8705 6907
Japan : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

The partner of choice for pharmaceutical companies

Get drugs to market faster

Our unique strengths

Identify market opportunities

Capitalize on treatment trends

Approach reimbursement proactively

View competitor activity

Relevant products

Below are the Product List

Thought leadership

Awareness

Lead generation

Pharma Intelligence latest insights

Latest headlines

Next steps

This is Contactus Section

Request a live demo

How can we help you?

Pharma Report Store